Patents Assigned to University of Zurich
-
Patent number: 9115370Abstract: The present invention relates to polynucleotides encoding adult plant pathogen resistance proteins. Also provided are transgenic plants expressing these polynucleotides to enhance the resistance of the plants to pathogens.Type: GrantFiled: October 9, 2013Date of Patent: August 25, 2015Assignees: Grains Research and Development Corporation, Commonwealth Scientific and Industrial Research Organisation, University of ZurichInventors: Evans Lagudah, Wolfgang Spielmeyer, Beat Keller, Simon Krattinger
-
Publication number: 20150232542Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: January 8, 2015Publication date: August 20, 2015Applicants: Biogen Idec International Neuroscience GmbH, University of ZurichInventors: Andreas WEIHOFEN, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20150147343Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: ApplicationFiled: July 2, 2014Publication date: May 28, 2015Applicant: University of ZurichInventors: Roger NITSCH, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Patent number: 9034333Abstract: A novel method for validating the utility of a drug in the treatment of inflammatory and cardiovascular diseases is described.Type: GrantFiled: August 29, 2011Date of Patent: May 19, 2015Assignee: University of ZurichInventors: Chad Brokopp, Simon Hoerstrup
-
Patent number: 8961924Abstract: A method for synthesizing a complex having the formula: [L3MO3]? wherein L3 represents a tridentate ligand, M represents a metal selected from Tc an Re, and n is a charge from ?2 to +1, the method comprising: a) reaction of pertechnetate or perrhenate with a reducing agent and L3, or b) reaction of pertechnetate or perrhenate with a Lewis acid and L3, wherein the synthesis (a) or (b) is carried out in an aqueous medium.Type: GrantFiled: March 10, 2009Date of Patent: February 24, 2015Assignee: University of ZurichInventors: Roger Alberto, Henrik Braband
-
Patent number: 8940272Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: October 11, 2011Date of Patent: January 27, 2015Assignees: University of Zurich, Biogen Idec International Neuroscience GmbHInventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
-
Patent number: 8940276Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: December 21, 2009Date of Patent: January 27, 2015Assignees: Biogen Idec International Neuroscience GmbH, University of ZurichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Patent number: 8933051Abstract: The invention relates to microRNA-34a and related microRNAs for use in the treatment of B-cell lymphoma. Likewise it relates to microRNA-34a for use in the preparation of a medicament for the treatment of B-cell lymphoma, and for a method of treatment of B-cell lymphoma comprising administering microRNA-34a. These claims are based on the observation that microRNA-34a shows strong anti-proliferative effects when overexpressed in diffuse large B-cell lymphoma (gDLBCL) cell lines, or when delivered intratumorally or systemically in xenograft models of DLBCL.Type: GrantFiled: September 29, 2011Date of Patent: January 13, 2015Assignee: University of ZurichInventors: Vanessa Craig, Anne Mueller
-
Publication number: 20140369940Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: June 22, 2012Publication date: December 18, 2014Applicants: University of Zurich, Biogen IDEC International Neuroscience GmbHInventors: Andreas Weihofen, Jan Grimm, Cristoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Patent number: 8906367Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: GrantFiled: January 7, 2008Date of Patent: December 9, 2014Assignee: University of ZurichInventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Patent number: 8846577Abstract: The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of Gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cDNA libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds. The invention further relates to phage or phagemid vectors useful in the method comprising a gene construct coding for a fusion polypeptide comprising the polypeptide to be displayed on the phage particle and an N-terminal signal sequence promoting cotranslational translocation.Type: GrantFiled: June 30, 2006Date of Patent: September 30, 2014Assignee: University of ZurichInventors: Daniel Steiner, Patrik Forrer, Michael T. Stumpp, Andreas Plückthun
-
Publication number: 20140178417Abstract: The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotixin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.Type: ApplicationFiled: August 29, 2013Publication date: June 26, 2014Applicant: University of ZurichInventors: Uwe ZANGEMEISTER-WITTKE, Claudio DI PAOLO, Dominique Christine TSCHUDI, Nicholas Ronald GLOVER, Dimitri Peter FITSIALOS
-
Patent number: 8753641Abstract: The invention relates to molecules for treatment and diagnosis of tumors and malignancies, comprising a tumor seeking biomolecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is preferably a radioactive metal, to the use of these molecules and to therapeutic and diagnostic compositions containing them.Type: GrantFiled: July 20, 2009Date of Patent: June 17, 2014Assignee: University of ZurichInventors: Roger Ariel Alberto, Pascal Jean-Marie Hafliger
-
Patent number: 8711337Abstract: The invention is a passive method to measure the translational speed of a visual scene using the distribution of light intensities. The invention combines two principles: perspective distortion matching over a broad field of view, and temporal filtering variation. The perspective distortion of the image is used to sample the visual scene at different linear wavelengths over the visual field. The result is a spatial sensitivity map of the visual scene. The obtained signal is then temporally filtered with cutoff frequencies proportional to the spatial sensitivity. The final result is a wide-spectrum computation of a ratio between temporal and linear spatial frequencies, in other words linear speed. The technique does not require the emission of a reference signal and is independent from external infrastructures.Type: GrantFiled: December 16, 2009Date of Patent: April 29, 2014Assignee: University of ZurichInventor: Nicola Rohrseitz
-
Publication number: 20140106297Abstract: A dental bur and method for removing a soft deposit from a tooth or an implant, the bur having a shank adapted to be connected to a rotary device. A head extends from the shank. The head has a material hardness adapted to remove soft deposits attached to the tooth but deflect against the tooth. Furthermore, the head is sized for insertion into a periodontal pocket adjacent to the tooth without surgery. Thus, the dental bur may be rotated against the tooth for removing the soft deposits but deflect and/or wear against the tooth for preventing damage to the tooth.Type: ApplicationFiled: March 15, 2013Publication date: April 17, 2014Applicants: University of Zurich, KerrHawe SAInventors: Patrick R. Schmidlin, Beat Kilcher, Marco Da Rold
-
Patent number: 8698092Abstract: A motion recognizing apparatus and method are provided. According to an aspect, a motion recognizing apparatus may include: an optical sensor configured to sense at least a portion of a subject where a motion occurs and to output one or more events in response thereto; a motion tracing unit configured to trace a motion locus of the portion where the motion occurs based on the one or more outputted events; and a motion pattern determining unit configured to determine a motion pattern of the portion where the motion occurs based on the traced motion locus.Type: GrantFiled: September 9, 2011Date of Patent: April 15, 2014Assignees: Samsung Electronics Co., Ltd., University of ZurichInventors: Jun Haeng Lee, Delbruck Tobi, Hyunsurk Ryu, Keun Joo Park, Chang Woo Shin
-
Publication number: 20140101791Abstract: The present invention relates to polynucleotides encoding adult plant pathogen resistance proteins. Also provided are transgenic plants expressing these polynucleotides to enhance the resistance of the plants to pathogens.Type: ApplicationFiled: October 9, 2013Publication date: April 10, 2014Applicants: Grains Research and Development Corporation, University of Zurich, Commonwealth Scientific and Industrial Research OrganisationInventors: EVANS LAGUDAH, WOLFGANG SPIELMEYER, BEAT KELLER, SIMON KRATTINGER
-
Publication number: 20140093514Abstract: The present invention relates to MAGEA3 binding antibodies.Type: ApplicationFiled: May 23, 2012Publication date: April 3, 2014Applicants: University of Zurich, CT ATLANTIC LTD.Inventors: Christoph Esslinger, Michael Höcker, Martin Treder, Alexander Knuth, Elke Jäger
-
Publication number: 20140074099Abstract: The present invention relates to surgical guides, and methods for their manufacture. The invention provides surgical guides comprising at least one alignment element and at least two guiding elements. The alignment elements can constrain the guiding elements into an initial position which guides a surgical operation, and optionally at least one target position different from the initial position.Type: ApplicationFiled: November 14, 2013Publication date: March 13, 2014Applicants: University of Zurich, MATERIALISE N.V.Inventors: Lara Vigneron, Louis James Keppler, Claudio Fadri Dora, Stephan Herrman Wirth, Elke Antonia Maria Giets
-
Patent number: 8647641Abstract: The present invention relates to the use of live mycobacterium of the M. tuberculosis complex for preparing a medicament, wherein the function of the zmp1-gene is inactivated, pharmaceutical compositions prepared from such mycobacteria as well as a method for the treatment and/or prophylaxis of a disease or medical condition using said pharmaceutical composition.Type: GrantFiled: October 9, 2009Date of Patent: February 11, 2014Assignee: University of ZurichInventors: Erik Boettger, Peter Sander